Tetra Bio-Pharma Inc. (
CSE: C.TBP,
OTCQB: GRPOF,
Forum) said Wednesday it has signed a definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation.
The combined total market potential for both products in the U.S.A. in 2014 is estimated at over US$5.5 billion, the company said in a press release.
More information can be found
here.
Tetra-Bio Pharma is a multi-subsidiary publicly traded company engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
The Ontario-based company was in the news recently when it and and
Aphria Inc. (
TSX: V.APH,
OTCQB: APHQF,
Forum) announced plans for
the joint distribution of dried medical cannabis in the maritime provinces and Quebec.
Tetra and Aphria will enter into a joint supply agreement, the companies said in a press release.
Full Disclosure: Tetra Bio-Pharma Inc. is a paid client of Stockhouse Publishing.